Extension of Time to File SOU

PTO Form 1581 (Rev 9/2005)

OMB No. 0651-0054 (Exp. 10/31/2017)

---

PTO Form 1581 (Rev 9/2005)

OMB No. 0651-0054 (Exp. 10/31/2017)

SOU Extension Request
(15 U.S.C. Section 1051(d))

To the Commissioner for Trademarks:

MARK: XYRALID
SERIAL NUMBER: 86023287

The applicant, Innovus Pharmaceuticals, Inc., having an address of
      9171 Towne Centre Drive, Suite 440
      San Diego, California 92122
      United States
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 02/11/2014.

For International Class 005:
Current identification: Anesthetics for non-surgical use; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of rectal pain caused by hemorrhoids; Pharmaceutical skin lotions; Topical anesthetics

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the first extension request.

The applicant's current Correspondence Information: INNOVUS PHARMACEUTICALS, INC.
      9171 Towne Centre Drive, Suite 440
      San Diego, California (CA) 92122
      United States (USX)

The applicant's proposed Correspondence Information: INNOVUS PHARMACEUTICALS, INC.
      9171 Towne Centre Drive, Suite 440
      San Diego, California (CA) 92122
      United States (USX)


The phone number is 858-964-5123.

The fax number is 858-249-7879.

The email address is rberholtz@innovuspharma.com;vince@innovuspharma.com.


A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention to use or use through the applicant's related company or licensee the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other person has the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other person, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. Section 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Bassam Damaj/      Date Signed: 08/04/2014
Signatory's Name: Bassam Damaj
Signatory's Position: President and Chief Executive Officer
Signatory's Phone: 858-964-5123

RAM Sale Number: 86023287
RAM Accounting Date: 08/05/2014

Serial Number: 86023287
Internet Transmission Date: Mon Aug 04 16:23:38 EDT 2014
TEAS Stamp: USPTO/ESU-XX.XXX.XX.XXX-2014080416233899
2059-86023287-500d52027acf76b398627e66bf
879f0c34e8c8c9765d75dbec1484ad69ef7c784-
CC-2892-20140804160611172768